Logo image of GMTX

GEMINI THERAPEUTICS INC (GMTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GMTX - US36870G1058 - Common Stock

1.35 USD
0 (0%)
Last: 12/29/2022, 8:00:02 PM
1.32 USD
-0.03 (-2.22%)
After Hours: 12/29/2022, 8:00:02 PM
Fundamental Rating

3

Overall GMTX gets a fundamental rating of 3 out of 10. We evaluated GMTX against 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for GMTX as it has an excellent financial health rating, but there are worries on the profitability. GMTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • GMTX had negative earnings in the past year.
  • In the past year GMTX has reported a negative cash flow from operations.
GMTX Yearly Net Income VS EBIT VS OCF VS FCFGMTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 -20M -40M -60M

1.2 Ratios

  • GMTX has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GMTX Yearly ROA, ROE, ROICGMTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 -10 -20 -30 -40 -50

1.3 Margins

  • GMTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GMTX Yearly Profit, Operating, Gross MarginsGMTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021

More info and screens

8

2. Health

2.1 Basic Checks

  • GMTX has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, GMTX has a worse debt to assets ratio.
GMTX Yearly Shares OutstandingGMTX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 10M 20M 30M 40M
GMTX Yearly Total Debt VS Total AssetsGMTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 50M 100M

2.2 Solvency

  • An Altman-Z score of 21.03 indicates that GMTX is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 21.03, GMTX belongs to the best of the industry, outperforming 94.57% of the companies in the same industry.
  • There is no outstanding debt for GMTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 21.03
ROIC/WACCN/A
WACCN/A
GMTX Yearly LT Debt VS Equity VS FCFGMTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 71.49 indicates that GMTX has no problem at all paying its short term obligations.
  • GMTX's Current ratio of 71.49 is amongst the best of the industry. GMTX outperforms 99.53% of its industry peers.
  • GMTX has a Quick Ratio of 71.49. This indicates that GMTX is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 71.49, GMTX belongs to the best of the industry, outperforming 99.53% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 71.49
Quick Ratio 71.49
GMTX Yearly Current Assets VS Current LiabilitesGMTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 50M 100M

More info and screens

1

3. Growth

3.1 Past

  • GMTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.64%, which is quite impressive.
EPS 1Y (TTM)29.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, GMTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.85% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y81.97%
EPS Next 2Y36.14%
EPS Next 3Y23.09%
EPS Next 5Y12.85%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GMTX Yearly EPS VS EstimatesGMTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GMTX. In the last year negative earnings were reported.
  • Also next year GMTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GMTX Price Earnings VS Forward Price EarningsGMTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GMTX Per share dataGMTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as GMTX's earnings are expected to grow with 23.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.14%
EPS Next 3Y23.09%

More info and screens

0

5. Dividend

5.1 Amount

  • GMTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GEMINI THERAPEUTICS INC / GMTX FAQ

What is the ChartMill fundamental rating of GEMINI THERAPEUTICS INC (GMTX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to GMTX.


What is the valuation status of GEMINI THERAPEUTICS INC (GMTX) stock?

ChartMill assigns a valuation rating of 3 / 10 to GEMINI THERAPEUTICS INC (GMTX). This can be considered as Overvalued.


What is the profitability of GMTX stock?

GEMINI THERAPEUTICS INC (GMTX) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for GMTX stock?

The Earnings per Share (EPS) of GEMINI THERAPEUTICS INC (GMTX) is expected to grow by 81.97% in the next year.